Leela Barham and Tim Wilsdon discuss the potential impact that value-based pricing (VBP) may have in the UK and the broader implications for developing international models of Health Technology Assessment (HTA). The article can be found here:
Assessing the economic case for Alzheimer’s disease policy prioritisation
The analysis has highlighted specific areas where more urgent action is needed, specifically: Accelerating diagnosing patients at scale; Supporting expansion...
